Merck buying rights to Ambrilia HIV compound


CHICAGO, Oct 12 (Reuters) - Merck & Co. Inc. has agreed to acquire worldwide rights to Canadian biotech firm Ambrilia Biopharma Inc.'s HIV/AIDS protease inhibitor program, Ambrilia said on Thursday.

Merck will pay $17 million on signing and up to $215 million upon successful completion of development, clinical, regulatory and sales milestones, and royalties on all future product sales.

Merck will gain exclusive worldwide rights to Ambrilia's lead compound, PPL-100, which is currently in early clinical trials.


Read more HIV/AIDS News on